menu
    • menu
    [{"orgOrder":0,"company":"Vividion Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"VVD-130037","moa":"KEAP1\/Nrf2","graph1":"Oncology","graph2":"Phase I","graph3":"Vividion Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Vividion Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Vividion Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Vividion Therapeutics","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"VVD-130037","moa":"KEAP1\/Nrf2","graph1":"Oncology","graph2":"Phase I","graph3":"Vividion Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Vividion Therapeutics \/ Bayer AG","highestDevelopmentStatusID":"6","companyTruncated":"Vividion Therapeutics \/ Bayer AG"},{"orgOrder":0,"company":"Vividion Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"VVD-159642","moa":"RAS-PI3K-alpha","graph1":"Oncology","graph2":"Phase I","graph3":"Vividion Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Vividion Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Vividion Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Vividion Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Sotorasib","moa":"||RAS-PI3K-alpha","graph1":"Oncology","graph2":"Phase I","graph3":"Vividion Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Vividion Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Vividion Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Vividion Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"VVD-130850","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Vividion Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Vividion Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Vividion Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Vividion Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Vividion Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Vividion Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Vividion Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Vividion Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Undisclosed","year":"2025","type":"Licensing Agreement","leadProduct":"VVD-214","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Vividion Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vividion Therapeutics \/ Vividion Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Vividion Therapeutics \/ Vividion Therapeutics"},{"orgOrder":0,"company":"Vividion Therapeutics","sponsor":"Bayer AG","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Vividion Therapeutics","amount2":2,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":2,"dosageForm":"Undisclosed","sponsorNew":"Vividion Therapeutics \/ Bayer AG","highestDevelopmentStatusID":"4","companyTruncated":"Vividion Therapeutics \/ Bayer AG"},{"orgOrder":0,"company":"Vividion Therapeutics","sponsor":"Tavros Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Vividion Therapeutics","amount2":0.45000000000000001,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.45000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Vividion Therapeutics \/ Vividion Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"Vividion Therapeutics \/ Vividion Therapeutics"},{"orgOrder":0,"company":"Vividion Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Vividion Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vividion Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"4","companyTruncated":"Vividion Therapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Vividion Therapeutics","sponsor":"Tavros Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Vividion Therapeutics","amount2":0.45000000000000001,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.45000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Vividion Therapeutics \/ Vividion Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"Vividion Therapeutics \/ Vividion Therapeutics"},{"orgOrder":0,"company":"Vividion Therapeutics","sponsor":"Tavros Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Vividion Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vividion Therapeutics \/ Vividion Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"Vividion Therapeutics \/ Vividion Therapeutics"},{"orgOrder":0,"company":"Vividion Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Vividion Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vividion Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Vividion Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Vividion Therapeutics","sponsor":"Logos Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Series C Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Vividion Therapeutics","amount2":0.14000000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.14000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Vividion Therapeutics \/ Logos Capital","highestDevelopmentStatusID":"4","companyTruncated":"Vividion Therapeutics \/ Logos Capital"}]

    Find Clinical Drug Pipeline Developments & Deals by Vividion Therapeutics

    Menu

    Vividion Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Vividion Therapeutics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Vividion Therapeutics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VVD-214,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : F. Hoffmann-La Roche

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Vividion and Bayer Further Strengthen Oncology Development Pipeline

                            Details : Under the licensing agreement, Vividion secured exclusive worldwide rights to develop and commercialize the clinical-stage Werner helicase (WRN) covalent inhibitor VVD-214 (RO7589831).

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            June 04, 2025

                            Lead Product(s) : VVD-214,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : F. Hoffmann-La Roche

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Vividion Therapeutics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Vividion Therapeutics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VVD-159642,Sotorasib

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Vividion Doses First Patient with RAS-PI3K Inhibitor in Phase I

                            Details : VVD-159642 is an investigational oral RAS-PI3Kα inhibitor, which is currently being evaluated for the treatment of RAS-driven cancers.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 03, 2025

                            Lead Product(s) : VVD-159642,Sotorasib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Vividion Therapeutics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Vividion Therapeutics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VVD-159642

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-159642 in Participants With Advanc...

                            Details : VVD-159642 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 03, 2025

                            Lead Product(s) : VVD-159642

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Vividion Therapeutics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Vividion Therapeutics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery Platform

                            Recipient : Tavros Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Vividion Acquires Tavros to Enhance Functional Genomics Drug Discovery

                            Details : Through the acquisition, Vividion will utilize Tavros Therapeutics' precision oncology platform to focus on developing promising drug targets for cancer treatment.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            January 08, 2025

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery Platform

                            Recipient : Tavros Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Vividion Therapeutics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Vividion Therapeutics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery Platform

                            Recipient : Tavros Therapeutics

                            Deal Size : $448.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Tavros Therapeutics Achieves Two Milestone Payments in Collaboration with Vividion

                            Details : The collaboration aims to deliver novel precision therapeutics capable of addressing cancer-causing proteins that have eluded traditional small molecule drugs.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : $17.5 million

                            May 14, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery Platform

                            Recipient : Tavros Therapeutics

                            Deal Size : $448.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Vividion Therapeutics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Vividion Therapeutics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VVD-130850,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Vividion Starts Phase I Trial of STAT3 Inhibitor in Advanced Solid and Hematologic Tumors

                            Details : VVD-130850 is an investigational oral small molecule STAT3 inhibitor in phase 1 trials with pembrolizumab for advanced solid tumors and hematologic tumors.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 06, 2024

                            Lead Product(s) : VVD-130850,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Vividion Therapeutics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Vividion Therapeutics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VVD-130850

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130850 in Participants With Advanc...

                            Details : VVD-130850 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 03, 2024

                            Lead Product(s) : VVD-130850

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Vividion Therapeutics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Vividion Therapeutics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VVD-130037

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Bayer AG

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Vividion Therapeutics Starts Phase I Clinical Trial in Advanced Solid Tumors with KEAP1 Activator

                            Details : VVD-130037 is the investigational oral Kelch-like ECH Associated Protein 1 (KEAP1) activator, which is investigated for the treatment of advanced solid tumors.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 18, 2023

                            Lead Product(s) : VVD-130037

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Bayer AG

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Vividion Therapeutics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Vividion Therapeutics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VVD-130037

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanc...

                            Details : VVD-130037 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 20, 2023

                            Lead Product(s) : VVD-130037

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Vividion Therapeutics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Vividion Therapeutics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery

                            Recipient : Tavros Therapeutics

                            Deal Size : $448.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Tavros Therapeutics and Vividion Therapeutics Announce Strategic Collaboration to Discover and Enhance Targete...

                            Details : Tavros leverages its functional and computational genomics technologies to uncover unique vulnerabilities within tumors to discover novel targets and biomarkers in areas of high unmet clinical need and identify novel clinical positioning strategies for e...

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : $17.5 million

                            October 12, 2022

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery

                            Recipient : Tavros Therapeutics

                            Deal Size : $448.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth